Physician profile
Saima Baig
NPI 1033619044
$12,208.05
in general payments reported to CMS, 2019-2025
34 companies · $2,403 in 2025
The $2,403 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,845 · 2022: $2,321 · 2023: $2,162 · 2024: $2,477 · 2025: $2,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,809 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,808.61 |
| Education | $233.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,140.64 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,458.81 | 2021-2025 | Ingrezza |
| Abbvie INC. | $1,265.82 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,154.78 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,106.46 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,043.12 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $525.35 | 2021-2022 | |
| Lundbeck LLC | $455.23 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $398.94 | 2021-2025 | Fanapt |
| Acadia Pharmaceuticals INC | $398.06 | 2022-2024 | Nuplazid |
| Axsome Therapeutics, INC. | $316.51 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $304.18 | 2021-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $281.45 | 2021-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $231.98 | 2022-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $203.52 | 2024-2025 | Cobenfy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $188.32 | 2021-2025 | Aplenzin |
| Tris Pharma INC | $87.97 | 2023-2024 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $81.39 | 2021 | |
| Merck Sharp & Dohme LLC | $74.43 | 2021 | |
| Noven Therapeutics, LLC | $70.43 | 2021-2025 | Xelstrym, Secuado |
| Adlon Therapeutics L.P. | $61.07 | 2021 | |
| Indivior INC. | $45.82 | 2021 | |
| Neos Therapeutics, LP | $44.39 | 2022-2023 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $42.00 | 2021 | |
| Almatica Pharma LLC | $40.80 | 2021-2023 | Loreev Xr |
| Validus Pharmaceuticals LLC | $31.87 | 2025 | Lopressor |
| Orexo US, INC. | $28.36 | 2021 | |
| Noven Pharmaceuticals, INC. | $22.45 | 2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $20.60 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $20.00 | 2024 | |
| Genentech USA, INC. | $19.11 | 2022 | |
| Luye Pharma (USA) LTD. | $18.70 | 2025 | Erzofri Extended-Release |
| Idorsia Pharmaceuticals US INC | $13.57 | 2023 | Quviviq |
| Eisai INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saima Baig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.